4basebio UK Societas Director/PDMR Shareholding
July 01 2021 - 11:09AM
UK Regulatory
TIDM4BB
01 July 2021
4basebio UK Societas
(the "Company")
Director's Dealing
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on
exploiting its intellectual property in the field of gene therapies and DNA
vaccines, announces that, on 1 July 2021, Heikki Lanckriet, chief executive
officer, acquired 3,450 ordinary shares at an average price of 467 pence per
share on behalf of persons closely associated with him.
As a result of the acquisition of ordinary shares, Heikki Lanckriet's
beneficial holding, including shares held by persons closely associated with
him, comprises 1,243,453 ordinary shares representing 10.10 per cent. of the
Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.
For further enquiries, please contact:
4basebio UK Societas +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated +44 (0)20 7213 0880
Adviser)
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker) +44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte
Sutcliffe
Walbrook PR +44 (0)20 7933 8780
Anna Dunphy / Paul McManus Mob: +44 (0)7876 441 001 / +44 (0)7980 541
893
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1. Details of the person discharging managerial responsibilities/person
closely associated
a. Name Heikki
Lanckriet
2. Reason for notification
a. Position/Status Chief Executive
Officer
b. Initial notification/ Amendment Initial
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name 4basebio UK
Societas
b. LEI
2138005D5SAG8FIR6G91
4. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transactions have been conducted
a. Description of the financial instrument, type Ordinary Shares of
instrument
Identification Code ISIN: GB00BLD8ZL39
b. Nature of the transaction Acquisition of ordinary
shares
c. Price(s) and volume(s) Volume(s) Price (p)
a. 1,500 467p
b. 650 467p
c. 650 467p
d. 650 467p
d. Aggregated information
- Aggregated Volume 3,450
- Price 467 pence per share
e. Date of the transaction 1/7/2021
f. Place of the transaction London Stock Exchange, AIM
END
(END) Dow Jones Newswires
July 01, 2021 11:09 ET (15:09 GMT)
4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2024 to May 2024
4basebio (LSE:4BB)
Historical Stock Chart
From May 2023 to May 2024